Seeking Alpha

SA contributor Valuentum joins Bernstein in defending Celgene (CELG -11.9% to $59.15), which is...

SA contributor Valuentum joins Bernstein in defending Celgene (CELG -11.9% to $59.15), which is hurting badly following its EU Revlimid bombshell today. Valuentum says the share is undervalued and is attractive at below $65. "Firms that generate a free cash flow margin above 5% are usually considered cash cows." Celgene's 3-year average is 30.6% .
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|